Dermacyte Liquid

Dermacyte Liquid (MTX-001) is a cell-free amniotic fluid (cfAF) biologic developed by Merakris Therapeutics for the treatment of chronic wounds and cutaneous ulcers. Derived from full-term human amniotic fluid, the product contains a complex mixture of regenerative proteins, cytokines, and growth factors that modulate the wound environment. It is administered via subcutaneous injection and works by inhibiting myofibroblast activation (MFA) and epithelial-mesenchymal transition (EMT), processes that are critical in both wound healing and the progression of fibrosis. Clinical studies have focused on its efficacy in treating non-healing venous stasis ulcers, while preclinical research has explored its potential in mitigating liver fibrosis by dampening hepatic stellate cell activation and preserving hepatocyte metabolic function.

Brand names

Dermacyte Liquid

Other names

cell-free amniotic fluidcfAF